Replies to post #16936 on MannKind Corp. (MNKD)

[TREND1]

MNKD UPDATE

1 REV = 0 It is all about AFREZZA sales.
2 29 FOLD INCREASE REQUIRED in AFREZZA sales to break even post 16339
3 AFREZZA (70% HIGHER) still at tier 3 insurance.
4 No FDA approval FOR NEW LABEL for AFREZZA. A1C THE SAME per FDA.
5 NO completion of lung cancer study promised FDA
6 NO FDA Approval of AFREZZA for Pediatrics.
7 $25 million minimum cash required for loan obligations. ($185.4 million).
8 92 Doctors writing 3 scripts per week.post 16425 16462
9 INHALABLE POWDER FOR GLP-1 FOR TREATMENT OF DIABETES. POST 16539
10 18 LONG TRADES FOR OCT NOV DEC 2015 POST 16629
11 SNY drops AFREZZA(MNKD) JAN 5, 2016
12 Sanofi’s says the commercialization of AFREZZA is no longer economically viable
in the United States. post 16851
13 MNKD will go BK in 2016. IMHO.